The FDA cleared the first new treatment for Alzheimer's in nearly two decades on Monday, sending shares of maker Biogen up 38% and adding $16.5B in market value. The company claims that Aduhelm, which has the molecular name aducanumab, slows down the memory-robbing disease by breaking up clumps of plaque formed on the brain called amyloid. The approval came just in time for Biogen, which is dealing with declining sales and the loss of patent protection for its top-selling drug. Despite the drug's questionable efficacy, Biogen said it would charge about $56,000 a year per patient (and wouldn't hike prices for four years).
Amazon's Sidewalk project goes live today without asking your permission. The "neighborhood network" pools local Internet connections from millions of Amazon Echo smart speakers and Ring devices to let smart devices have a wider range of operation. While users have not been asked to opt-in, they could still turn the capability off, though their devices won't be able to access the network. Signals from all of Amazon's neighborhood devices join together to create what’s called a mesh network. The low-bandwidth wireless grid can stretch half a mile to connect hard-to-reach areas across urban and suburban America.
The Senate looks set to pass far-reaching China legislative package this week, in the broadest offensive push yet to counter increasing competition from China. The package, which initially had been expected to pass in late May before legislators punted it, looks to increase investment in research and development around advanced technology like artificial intelligence and funding for semiconductor production—necessary for just about any digital technology—closer to home.